Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Brecanavir (Primary) ; HIV protease inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms STRIVE
- Sponsors ViiV Healthcare
- 09 Oct 2008 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 23 Nov 2005 New trial record.